APA Citatie

Yu, T., & Dai, M. (2020). Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma. J Hematol.

Chicago Style citaat

Yu, Tsung-Ying, en Ming-Shen Dai. "Prolonged Remission By Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma." J Hematol 2020.

MLA citatie

Yu, Tsung-Ying, en Ming-Shen Dai. "Prolonged Remission By Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma." J Hematol 2020.